The disposition of the antitumor agent, sangivamycin, in mice.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000378:metabolism* / Q000652:urine; D001921:Brain / Q000378:metabolism; D004273:DNA, Neoplasm / Q000378:metabolism; D004912:Erythrocytes / Q000378:metabolism; D006207:Half-Life; D007275:Injections, Intravenous; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009206:Myocardium / Q000378:metabolism; D010710:Phosphates / Q000378:metabolism; D011741:Pyrimidine Nucleosides / Q000008:administration & dosage / Q000378:metabolism* / Q000652:urine; D011758:Pyrroles / Q000008:administration & dosage / Q000378:metabolism / Q000652:urine; D012334:RNA, Neoplasm / Q000378:metabolism; D012263:Ribonucleosides / Q000008:administration & dosage / Q000378:metabolism / Q000652:urine; D013154:Spleen / Q000378:metabolism; D013997:Time Factors; D014316:Tritium
D000903:Antibiotics, Antineoplastic; D004273:DNA, Neoplasm; D010710:Phosphates; D011741:Pyrimidine Nucleosides; D011758:Pyrroles; D012334:RNA, Neoplasm; D012263:Ribonucleosides; D014316:Tritium